Dr. Zanni is a psychologist and health systems specialist based in Alexandria, Virginia.
Unintentional weight loss, also known as wasting, affects 10% of adult outpatients, 13% of elderly outpatients, and 50% to 60% of long-term care patients.1 This type of weight loss decreases functional status and quality of life, with mortality rates of 7% to 31%.1,2 As a symptom, unintentional weight loss suggests several diseases. Cancer is the leading cause (24% to 38% of cases), followed by gastrointestinal (10%) and endocrine (8%) disorders. 1 Bulimia, anorexia, depression, and mania also are associated with weight loss. Wasting's etiology is unknown in 25% of cases.3
Patient assessment always includes oral examination, nutritional evaluation, and drug regimen review. Agents associated with drug-induced weight loss include selective serotonin reuptake inhibitors; cardiac agents such as furosemide, digoxin, and bepridil; amphetamines and appetite suppressants; benzodiazepines; diuretics; psychotropics; insulin; and anti-inflammatories.4
For patients with unknown etiology or conditions unresponsive to treatment, reversing and/or preventing weight loss become the treatment focus (Table). Drugs generally are avoided initially, especially among elders.5 The primary intervention—increasing food intake to 100% of recommended daily allowances and adding nutritional supplements—usually leads to short-term weight gain, but data demonstrating long-term impact are inconsistent.3
Most data supporting pharmacologic agents come from small studies. Pharmacologic management results in short-term weight gain (approximately 3-7 lbs)3 without improving long-term health and mortality. Side effects from orexigenic (appetite-stimulating) and anabolic medications limit their use. Cyproheptadine and dronabinol may promote weight gain; central nervous system toxicity is a concern. Patients receiving megestrol and dronabinol usually gain weight, but weight is primarily adipose tissue, not lean body mass. Human growth hormone and other anabolic agents promote weight gain but are associated with increased mortality. Anticytokine therapies, antileptin therapies, and anti-inflammatory medications are under investigation.3
Nutritional supplements remain the primary intervention. Because insufficient data exist on the long-term benefits and side effects of pharmacologic approaches, caution is advised. Patients and their families often believe unintentional weight loss accompanies normal aging. Pharmacists' counseling must emphasize the seriousness of wasting.
Adapted from references 1 and 2.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs